<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Denileukin diftitox (DAB(389)IL-2 or Ontak) is a synthetic fusion protein with demonstrated efficacy in a number of <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, including non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We report the case of a 45-year-old man with progressive follicular large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> following an autologous stem cell transplant treated with denileukin diftitox who developed a fatal <z:hpo ids='HP_0000988'>skin rash</z:hpo> associated with extensive <z:hpo ids='HP_0010783'>erythema</z:hpo>, <z:hpo ids='HP_0000969'>edema</z:hpo> and large bullae involving his entire body </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical features and pathology were compatible with <z:e sem="disease" ids="C0014518" disease_type="Disease or Syndrome" abbrv="TEN">toxic epidermal necrolysis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This is the first reported case of <z:e sem="disease" ids="C0014518" disease_type="Disease or Syndrome" abbrv="TEN">toxic epidermal necrolysis</z:e> in the literature associated with denileukin diftitox </plain></SENT>
</text></document>